Key regions: Brazil, India, Australia, United States, United Kingdom
The demand for antiviral drugs in Eastern Europe has been steadily increasing in recent years.
Customer preferences: One of the main drivers of this trend is the growing awareness of the importance of preventative healthcare. As more people become aware of the potential risks associated with viral infections, they are increasingly seeking out antiviral drugs as a way to protect themselves and their families.
Trends in the market: Another key trend in the antiviral drugs market in Eastern Europe is the growing popularity of generic drugs. This is largely due to the fact that many people in the region are looking for more affordable healthcare options. As a result, many pharmaceutical companies are now focusing on producing generic versions of popular antiviral drugs in order to meet this growing demand.
Local special circumstances: In addition to these broader trends, there are also a number of local factors that are driving the growth of the antiviral drugs market in Eastern Europe. For example, many countries in the region have experienced outbreaks of viral infections in recent years, which has led to an increased demand for antiviral drugs. Additionally, many healthcare providers in the region are now offering antiviral drugs as part of their standard treatment protocols, which has also contributed to the growth of the market.
Underlying macroeconomic factors: At the same time, there are also a number of underlying macroeconomic factors that are contributing to the growth of the antiviral drugs market in Eastern Europe. For example, many countries in the region are experiencing strong economic growth, which is leading to increased spending on healthcare. Additionally, many governments in the region are now investing more heavily in their healthcare systems, which is also contributing to the growth of the market. Overall, these factors are expected to continue driving growth in the antiviral drugs market in Eastern Europe in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
